Skip to main content
SpringerLink
Log in

Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19

  • Original Article
  • Interleukin-2, Anti-CD19 Antibody, Monoclonal Therapy
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Seven patients with low-grade non-Hodgkin's lymphoma were treated with a combination of a murine monoclonal antibody directed against the B-cell-specific antigen CD19 (CLB-CD10), given twice weekly, and continuous infusion of low-dose recombinant interleukin-2 (rIL-2). We demonstrated stable serum CLB-CD19 levels throughout the 12 weeks of treatment, and homing of the antibody into the tumour sites. A variable degree of antigenic modulation was noted. Prolonged treatment resulted in a sustained increase in the number of natural killer cells in the circulation with enhanced cytotoxic capacity, including antibody-dependent cellular cytotoxicity. During the first weeks of treatment, T cell activation occurred in the majority of patients. Toxicity was related to the rIL-2 treatment and consisted of transient constitutional symptoms and a flu-like syndrome without organ dysfunction. A partial remission occurred in one patient, and in another patient who was primarily leukaemic a greater than 50% reduction of circulating B cells was noted. An antitumour effect occurred early during treatment and could not be related to rIL-2-induced modulation of natural killer cell or T lymphocyte activation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allison MAK, Jones SE, McGuffy P (1989) Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. J Clin Oncol 7:75

    PubMed  Google Scholar 

  2. Bajorin DF, Chapman PB, Wong G, Coit DG, Kunicka J, Dimaggio J, Cordon-Cardo C, Urmacher C, Dantes L, Templeton MA, Liu J, Oettgen HF, Houghton AN (1990) Phase I evaluation of a combination of monclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 50:7490

    PubMed  Google Scholar 

  3. Berinstein N, Levy R (1987) Treatment of a murine B cell lymphoma with monoclonal antibodies and IL-2. J Immunol 139:971

    PubMed  Google Scholar 

  4. Berinstein N, Starnes CO, Levy R (1988) Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. J Immunol 140:2839

    PubMed  Google Scholar 

  5. Bernstein ZP, Vaickus L, Friedman N, Goldrosen MH, Watanabe H, Rahman R, Arbuck SG, Sweeney J, Vesper D, Henderson ED, Zeffren J, Dennin RA, Levitt D, Foon KA (1991) Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease. J Immunother 10:141

    PubMed  Google Scholar 

  6. Blottiere HM, Douillard J-Y, Koprowski H, Steplewski Z (1990) Humoral and cellular responses of colorectal patients treated with monoclonal antibodies and interferon-γ. Cancer Immunol Immunother 32:29

    PubMed  Google Scholar 

  7. Brown SL, Miller RA, Horning SJ, Czerwinsky D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R (1989) Treatment of B-cell lymphomas with anti-idiotype antibodies alone or in combination with alpha interferon. Blood 73:651

    PubMed  Google Scholar 

  8. Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, Smith K, Ritz J (1991) Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 9:2110

    PubMed  Google Scholar 

  9. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, Smith KA, Ritz J (1993) Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2 J Clin Invest 91:123

    PubMed  Google Scholar 

  10. De Rie MA, Schumacher TNM, Van Schijndel GMW, Van Lier RAW, Miedema F (1989) Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell Immunol 118:368

    PubMed  Google Scholar 

  11. Dillmann RO (1989) Monoclonal antibodies for treating cancer. Ann Intern Med 111:592

    PubMed  Google Scholar 

  12. Duggan DB, Santarelli MT, Zamkoff K, Lichtman S, Ellerton J, Cooper R, Poies B, Anderson JR, Bloomfield CD, Peterson BA, Gottlieb AJ (1992) A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B. J Immunother 12:115

    PubMed  Google Scholar 

  13. Gottlieb DJ, Prentice HG, Heslop HE, Bello C, Brenner MK (1992) IL-2 infusion abrogates humoral immune responses in humans. Clin Exp Immunol 87:493

    PubMed  Google Scholar 

  14. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blättler WA, Taylor JA, Nadler LM (1992) Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 79:576

    PubMed  Google Scholar 

  15. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863

    PubMed  Google Scholar 

  16. Hekman A, Honselaar A, Vuist WMJ, Sein JJ, Rodenhuis S, Ten Bokkel Huinink WW, Somers R, Rümke P, Melief CJM (1991) Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 32:364

    PubMed  Google Scholar 

  17. Hu F, Epstein A, Naeve GS, Gill I, Martin S, Sherrod A, Nichols P, Chen D, Mazumder A, Levine AM (1989) A phase la clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 7:155

    PubMed  Google Scholar 

  18. Klempner MS, Noring R, Mier JW, Atkins B (1990) An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 322:959

    PubMed  Google Scholar 

  19. Kosmas C, Epenetos AA, Courtenay-Luck NS (1991) Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies targets. J Exp Med 167:345

    Google Scholar 

  20. Levy R, Miller RA (1990) Therapy of lymphoma directed at idiotypes. J Natl Cancer Inst Monogr 10:61

    PubMed  Google Scholar 

  21. Lim SH, Giles FJ, Smith MP, Goldstone AH (1991) Bacterial infections in lymphoma patients treated with recombinant interleukin-2. Acta Haematol 85:135

    PubMed  Google Scholar 

  22. Margolin KA, Aronson FR, Sznol M, Atkins MB, Ciobaum N, Fisher RI, Weiss GR, Doroshow JH, Bar MH, Hawkins MJ, Mier JW, Paietta E, Gaynor EP, Boldt DH (1991) Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immunother 10:214

    PubMed  Google Scholar 

  23. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R (1985) A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349

    PubMed  Google Scholar 

  24. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207

    PubMed  Google Scholar 

  25. Munn DH, Cheung N-KV (1987) Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47:6600

    PubMed  Google Scholar 

  26. Non-Hodgkin's lymphoma pathologic classification project (1982) National Cancer Institute sponsored study of classfication of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 49:2112

    Google Scholar 

  27. Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R (1987) Analysis of effector cells in human antibody dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol 381:3566

    Google Scholar 

  28. Pezzutto A, Dörken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA (1987) CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol 138:2793

    PubMed  Google Scholar 

  29. Press OW, Appelbaum F, Ledbetter JA, Marin PJ, Zarlin J, Kidd P, Thomas ED (1987) Monoclonal antibody IF5 [anti-CD20] serotherapy of human B cell lymphomas. Blood 69:584

    PubMed  Google Scholar 

  30. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSanted K, Porter B, Kidd P, Thomas ED (1989) Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7:1027

    PubMed  Google Scholar 

  31. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49:4906

    PubMed  Google Scholar 

  32. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS (1981) Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1:51

    PubMed  Google Scholar 

  33. Ritz J, Pesando JM, Sallan SE, Clawell LA, Notis-McConarty J, Rosenthal P, Schlossman SF (1981) Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58:141

    PubMed  Google Scholar 

  34. Sanda MG, Bolton E, Mulé JJ, Rosenberg SA (1992) In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells. J Immunother 12:132

    PubMed  Google Scholar 

  35. Scheinberg DA (1991) Current applications of monoclonal antibodies for the therapy of hematopoietic cancers. Curr Opin Immunol 3:679

    PubMed  Google Scholar 

  36. Scheinberg DA, Straus DJ, Yeh SD, Divgi C, Garin-Chesa P, Graham M, Pentlow K, Coit D, Oettgen HF, Old LJ (1990) A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. J Clin Oncol 8:792

    PubMed  Google Scholar 

  37. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J (1992) Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79:517

    PubMed  Google Scholar 

  38. Tourani J-M, Levy V, Briere J, Levy R, Franks C, Andrieu J-M (1991) Interleukin-2 therapy for refractory and relapsing lymphomas. Eur J Cancer 27:1676

    PubMed  Google Scholar 

  39. Uckun FM, Jascz W, Ambrus JL, Fauci AS, Gajl-Pecszalska K, Song CW, Wick MR, Myers DE, Waddick K, Ledbetter JA (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71:13

    PubMed  Google Scholar 

  40. Vaickus L, Biddle W, Cemerlik D, Foon KA (1990) Interferon gamma augments Lym-1 dependent granulocyte-mediated tumor cell lysis. Blood 75:2408

    PubMed  Google Scholar 

  41. Van Endert PM, Heilig B, Hämmerling G, Moldenhauer G (1992) Monoclonal antibodies to idiotype inhibit in vitro growth of human-B-cell lymphomas. Blood 79:129

    PubMed  Google Scholar 

  42. Vlasveld LT, Rankin EM, Hekman A, Rodenhuis S, Beijnen JH, Hilton AM, Dubbelman AC, Vyth-Dreese FA, Melief CJM (1992) A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I clinical aspects. Br J Cancer 65:744

    PubMed  Google Scholar 

  43. Vlasveld LT, Hekman A, Vyth-Dreese FA, Rankin EM, Scharenberg JGM, Voordouw AC, Sein JJ, Dellemijn TAM, Rodenshuis S, Melief CJM (1993) A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: immunologic aspects. Br. J Cancer 68:559

    PubMed  Google Scholar 

  44. Vuist WMJ, Van Buitenen F, De Rie MA, Hekman A, Rümke P Melief CJM (1988) Potentiation by interleukin 2 of Burkintt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibody in a mouse xenotransplantation model. Cancer Res 49:3783

    Google Scholar 

  45. Vyth-Dreese FA, Van der Reijden HJ, De Vries JE, (1982) Phorbol-ester-mediated induction and augmentation of mitogenesis and interleukin-2 production in human T-cell lymphoproliferative disease. Blood 60:1437

    PubMed  Google Scholar 

  46. Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA (1992) The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 10:33

    PubMed  Google Scholar 

  47. Ziegler LD, Palazzolo P, Cunningham J, Janus M, Itoh K, Hayakawa K Hellström I, Hellström KE, Nicaise C, Dennin R, Murray JL (1992) Phase 1 trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol 10:1470

    PubMed  Google Scholar 

  48. Zola H (1987) The surface antigens of human B lymphocytes. Immunol Today 8:308

    Google Scholar 

Download references

Author information

Author notes

  1. L. Tom Vlasveld

    Present address: Diaconessenhuis, Eindhoven, The Netherlands

  2. Cornelis J. M. Melief

    Present address: Department of Immunohaematology and Blood Bank, Academic Hospital, Leiden, The Netherlands

Authors and Affiliations

  1. Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

    L. Tom Vlasveld & L. Tom Vlasveld

  2. Division of Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

    Annemarie Hekman, Florry A. Vyth-Dreese, Cornelis J. M. Melief, Johan J. Sein, Arie C. Voordouw, Trees A. M. Dellemijn & Elaine M. Rankin

Authors
  1. L. Tom Vlasveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annemarie Hekman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Florry A. Vyth-Dreese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cornelis J. M. Melief
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Johan J. Sein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Arie C. Voordouw
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Trees A. M. Dellemijn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elaine M. Rankin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vlasveld, L.T., Hekman, A., Vyth-Dreese, F.A. et al. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol Immunother 40, 37–47 (1995). https://doi.org/10.1007/BF01517234

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01517234

Key words

Search

Navigation